I期临床-话题@MedSci

#I期临床#

570篇内容 | 7592人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果, objectType=article, longId=110765, objectId=c218110e6568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c218110e6568, replyNumber=0, likeNumber=75, createdTime=2018-03-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c218110e6568, moduleTitle=CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c218110e6568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652778, encodeId=167d1652e783f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=92, createdTime=2017-10-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652771, encodeId=f1411652e7179, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, objectType=article, longId=77492, objectId=45e5e749218, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45e5e749218, replyNumber=0, likeNumber=114, createdTime=2017-08-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45e5e749218, moduleTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45e5e749218)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652770, encodeId=58521652e70f7, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功, objectType=article, longId=77044, objectId=8f4ee7044a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f4ee7044a1, replyNumber=0, likeNumber=65, createdTime=2017-08-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f4ee7044a1, moduleTitle=喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f4ee7044a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652781, encodeId=780f1652e8161, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞艰难梭菌疫苗产品PF-06425090在II期临床收获激动人心数据, objectType=article, longId=88383, objectId=7d0588383e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d0588383e4, replyNumber=0, likeNumber=84, createdTime=2017-10-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d0588383e4, moduleTitle=辉瑞艰难梭菌疫苗产品PF-06425090在II期临床收获激动人心数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d0588383e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652787, encodeId=6d231652e8775, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Oncol：CPI-613用于转移性胰腺癌I期临床结果, objectType=article, longId=98249, objectId=79c4982492d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79c4982492d, replyNumber=0, likeNumber=62, createdTime=2017-09-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79c4982492d, moduleTitle=Lancet Oncol：CPI-613用于转移性胰腺癌I期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79c4982492d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652766, encodeId=e3531652e66a2, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据, objectType=article, longId=74630, objectId=4456e46306b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4456e46306b, replyNumber=0, likeNumber=102, createdTime=2016-10-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4456e46306b, moduleTitle=卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4456e46306b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652791, encodeId=00571652e9148, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, objectType=article, longId=102825, objectId=3eb2102825e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb2102825e6, replyNumber=0, likeNumber=77, createdTime=2017-09-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb2102825e6, moduleTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb2102825e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652786, encodeId=51bf1652e869e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=The Lancet Infectious Diseases：长效抗疟药DMS265的I期临床研究, objectType=article, longId=93929, objectId=4411939298a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4411939298a, replyNumber=0, likeNumber=84, createdTime=2018-03-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4411939298a, moduleTitle=The Lancet Infectious Diseases：长效抗疟药DMS265的I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4411939298a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652775, encodeId=56381652e75e4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, objectType=article, longId=78707, objectId=88a4e870731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88a4e870731, replyNumber=0, likeNumber=91, createdTime=2017-06-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88a4e870731, moduleTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88a4e870731)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652788, encodeId=15fb1652e88eb, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, objectType=article, longId=99073, objectId=0118990e3ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0118990e3ca, replyNumber=0, likeNumber=71, createdTime=2018-01-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0118990e3ca, moduleTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0118990e3ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652790, encodeId=68c71652e901a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Chest：西罗莫司和淋巴管肌瘤病中的自噬抑制：I期临床试验结果, objectType=article, longId=101487, objectId=0ee810148e65, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ee810148e65, replyNumber=0, likeNumber=94, createdTime=2017-09-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ee810148e65, moduleTitle=Chest：西罗莫司和淋巴管肌瘤病中的自噬抑制：I期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ee810148e65)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652783, encodeId=ab121652e83b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=安进新一代降脂药Repatha&nbspIII期临床显著降低高胆固醇患者机采需求, objectType=article, longId=91934, objectId=84fa919345f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84fa919345f, replyNumber=0, likeNumber=96, createdTime=2017-03-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84fa919345f, moduleTitle=安进新一代降脂药Repatha&nbspIII期临床显著降低高胆固醇患者机采需求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84fa919345f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652767, encodeId=24c01652e67ec, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Radius新型骨质疏松症药物abaloparatide III期临床获得成功，将成礼来重磅药物Forteo（特立帕肽）劲敌, objectType=article, longId=75431, objectId=5c87e54317c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c87e54317c, replyNumber=0, likeNumber=64, createdTime=2016-12-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c87e54317c, moduleTitle=Radius新型骨质疏松症药物abaloparatide III期临床获得成功，将成礼来重磅药物Forteo（特立帕肽）劲敌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c87e54317c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652780, encodeId=3c2a1652e801d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, objectType=article, longId=87131, objectId=d5598e13167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5598e13167, replyNumber=0, likeNumber=79, createdTime=2017-09-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5598e13167, moduleTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5598e13167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652776, encodeId=bd351652e76c8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=美国BARDA资助赛诺菲4320万美元资金，推动寨卡（Zika）疫苗进入II期临床开发, objectType=article, longId=79538, objectId=9109e953862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9109e953862, replyNumber=0, likeNumber=59, createdTime=2017-05-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9109e953862, moduleTitle=美国BARDA资助赛诺菲4320万美元资金，推动寨卡（Zika）疫苗进入II期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9109e953862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652784, encodeId=31931652e8403, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=重大打击！诺华急性心衰药物RLX030关键III期临床失败, objectType=article, longId=93796, objectId=066d93e9684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=066d93e9684, replyNumber=0, likeNumber=68, createdTime=2017-05-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=066d93e9684, moduleTitle=重大打击！诺华急性心衰药物RLX030关键III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=066d93e9684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652777, encodeId=002f1652e7757, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, objectType=article, longId=79539, objectId=ef32e9539e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef32e9539e8, replyNumber=0, likeNumber=74, createdTime=2017-01-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef32e9539e8, moduleTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef32e9539e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652756, encodeId=7ce61652e56cf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, objectType=article, longId=70647, objectId=2a45e0647b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a45e0647b2, replyNumber=0, likeNumber=68, createdTime=2017-04-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a45e0647b2, moduleTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a45e0647b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652769, encodeId=4bf71652e69e2, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, objectType=article, longId=77042, objectId=be26e7042b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be26e7042b9, replyNumber=0, likeNumber=74, createdTime=2016-09-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be26e7042b9, moduleTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be26e7042b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果

2018-03-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2017-10-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据

2017-08-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功

2017-08-06

仁者大医 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞艰难梭菌疫苗产品PF-06425090在II期临床收获激动人心数据

2017-10-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Oncol：CPI-613用于转移性胰腺癌I期临床结果

2017-09-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据

2016-10-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）

2017-09-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

The Lancet Infectious Diseases：长效抗疟药DMS265的I期临床研究

2018-03-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保

2017-06-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果

2018-01-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Chest：西罗莫司和淋巴管肌瘤病中的自噬抑制：I期临床试验结果

2017-09-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

安进新一代降脂药Repatha&nbspIII期临床显著降低高胆固醇患者机采需求

2017-03-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Radius新型骨质疏松症药物abaloparatide III期临床获得成功，将成礼来重磅药物Forteo（特立帕肽）劲敌

2016-12-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功

2017-09-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

美国BARDA资助赛诺菲4320万美元资金，推动寨卡（Zika）疫苗进入II期临床开发

2017-05-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

重大打击！诺华急性心衰药物RLX030关键III期临床失败

2017-05-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发

2017-01-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期

2017-04-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler

2016-09-09

科室
- - 订阅+
  - 更多科室
工具
服务